The Marcus Corporation filings document a Wisconsin public company with two operating divisions: Marcus Theatres and Marcus Hotels & Resorts. Form 8-K reports furnish quarterly and annual results, including theatre box-office activity, film-slate effects, hotel RevPAR, food-and-beverage operations and share repurchase authorization. Other 8-K disclosures record division leadership succession and board composition changes.
Proxy materials cover shareholder voting, director elections, board structure, executive compensation and related governance disclosures. The filing record also reflects capital-allocation matters and formal reporting around a business model that combines movie theatre operations, hospitality management and significant company-owned real estate assets.
Marcus Corp (MCS) is the issuer named in an amended Schedule 13G that lists 2,164,029 common shares, or 9.1% of the class, as beneficially owned. Separate entries report 2,139,536 shares (9%) for Orbis Investment Management Limited and 24,493 shares (0.1%) for Allan Gray Australia Pty Ltd. Both entities reported sole voting and sole dispositive power over their respective listed positions, with no shared voting or dispositive power.
Other persons are identified as having rights to dividends or sale proceeds from shares attributed to each reporting entity. The two entities filed together but stated they do not represent that they are a group; each also disclaimed beneficial ownership of shares attributed to the other.
The Marcus Corporation (MCS) is the issuer in an amended beneficial-ownership report listing American Century ETF Trust, American Century Investment Management, Inc. (ACIM), American Century Companies, Inc. (ACC), and Stowers Institute for Medical Research. As of September 30, 2026, American Century ETF Trust reported 1,408,013 shares, or 5.9%; ACIM, ACC, and Stowers each reported 1,473,301 shares, or 6.2%, with sole voting and dispositive power reported for each. ACIM is ACC’s wholly owned subsidiary, and Stowers is identified as ACC’s control entity.
The Marcus Corporation (MCS) reported third-quarter total revenues of $237.754 million for the three months ended September 30, 2026, compared with $210.151 million in 2025. Net earnings were $18.758 million, versus $16.230 million. Operating income was $30.283 million, compared with $22.731 million.
For the nine months ended September 30, 2026, total revenues were $623.902 million versus $564.960 million, and net earnings were $19.249 million versus $6.735 million. Net cash provided by operating activities was $77.190 million, compared with $35.400 million. Cash capital expenditures were $26.651 million, versus $60.809 million.
At September 30, 2026, cash and cash equivalents were $60.229 million, revolving-credit availability was $219.286 million, and net leverage was 0.79x; the company had no revolving borrowings. It reported $62.000 million of senior notes due within the next 12 months. A $0.183 million impairment loss was recorded for one theatre asset group, whose remaining net book value was $1.313 million. Management said it believes liquidity is sufficient to meet obligations and comply with debt covenants for at least 12 months from issuance of the financial statements.
Marcus Corporation (MCS) reported third-quarter 2026 revenue of $237.8 million, up 13.1% from third-quarter fiscal 2025, and operating income of $30.3 million, up 33.2%. Net earnings were $18.8 million, or $0.60 per diluted common share; Adjusted EBITDA, a non-GAAP measure, was $49.1 million. Those measures increased 15.6%, 15.4% and 21.5%, respectively.
Marcus Theatres generated $145.0 million in revenue, up 20.9%, and operating income of $22.2 million, a $9.9 million improvement. Hotels & Resorts reported $82.0 million in revenue before cost reimbursements, up 2.0%, while operating income decreased $1.0 million to $15.3 million. Severe storm damage at one property led to increased repair expenses and lost revenue.
For the first three quarters of 2026, revenue was $623.9 million, net earnings were $19.2 million and Adjusted EBITDA was $97.9 million, increases of 10.4%, 185.8% and 35.1%. The comparison period had five more operating days; its net earnings included a $3.0 million after-tax property insurance settlement gain.
MARCUS CORP director and ten-percent owner Diane M. Gershowitz reported that DG-LDJ Holdings, LLC sold 50,000 Common Stock shares on September 23, 2026, at a weighted-average price of $27.61 per share; reported prices ranged from $27.50 to $27.87. After the sale, the LLC reported 125,617 Common Stock shares. Other reported holdings include 37,429 Common Stock shares held directly, 1,881,677 Class B shares held by the LLC, 131,506 Class B shares held as trustee for her brother’s children, and 50,845 Class B shares held by the Ben and Celia Marcus 1992 Revocable Trust F/B/O Diane M. Gershowitz. Directly held options to buy Common Stock have exercise prices from $14.25 to $38.51. No Rule 10b5-1 plan is reported.
MARCUS CORP is the issuer named in a Form 144 notice by Diane M. Gershowitz, identified as Trustee, for a proposed sale of 50,000 common shares on account of DG-LDJ Holdings LLC. The notice lists an aggregate market value of $1,389,000 and September 23, 2026, as the approximate sale date.
The sale table names Mesirow Financial Inc. and NYSE, and lists 23,958,686 common shares outstanding. The 50,000 shares are listed as acquired on December 2, 1985, through a merger/acquisition described as “Marcus Corp (Stock for Stock).”
MARCUS CORP (MCS) reported that Sr Exec VP, Gen Counsel & Secy Thomas F. Kissinger executed a series of option exercises and related share withholdings on August 3, 2026. He exercised stock options for 24,400 shares at $27.00, 39,000 shares at $28.88, and 47,100 shares at $21.84 per share, receiving the same number of common shares in each case through net exercises. To pay the exercise price and tax withholding, the company withheld 22,499, 37,167, and 38,708 shares, respectively, using the $30.69 August 3, 2026 closing price. After these transactions, he continued to hold stock options on 17,000, 23,400, and 14,150 underlying shares, and indirectly held 547 common shares through a plan.
American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research report beneficial ownership of common stock of The Marcus Corporation. As of 06/30/2026, they collectively report beneficial ownership of 1,197,597 shares of common stock, representing 5.0% of the class. The reporting persons have sole voting power and sole dispositive power over 1,197,597 shares and no shared voting or dispositive power. Various advisory clients of American Century Investment Management, Inc. are entitled to receive dividends and sale proceeds for these shares, but no single client holds more than 5% of the class. American Century Investment Management, Inc. is a wholly owned subsidiary of American Century Companies, Inc., which is controlled by the Stowers Institute for Medical Research.
Orbis Investment Management Limited and Allan Gray Australia Pty Ltd report beneficial ownership of 2,189,129 shares of Marcus Corp common stock, representing 9.2% of the class. Orbis holds 2,164,636 shares and Allan Gray Australia holds 24,493 shares, each with sole voting and dispositive power over its respective holdings.
The two firms file together as non‑U.S. institutions equivalent to investment advisers but state that no reporting person is a member of a group for Section 13(d)(3) purposes and each disclaims beneficial ownership of shares held by the other.
Marcus Corp President and CEO Gregory S. Marcus reported receiving 1,249 shares of Class B Common Stock on August 7, 2026 via a transaction coded as a bona fide gift, held indirectly through his spouse, bringing that indirect position to 47,013 shares.
He also reported substantial existing positions, including 764,137 Class B shares held directly, 515,119 Common shares held directly, and multiple stock option grants over several years covering hundreds of thousands of underlying Common shares at exercise prices between $12.71 and $41.90.